Search the hub
Showing results for tags 'Adverse reaction'.
-
News Article
Global alert issued over fake Ozempic drugs
Patient Safety Learning posted a news article in News
A global alert about fake versions of Ozempic - which has become popular as a way of losing weight - has been issued by the World Health Organization (WHO). The drug is sometimes known as a "skinny jab" despite its main purpose being a treatment for type 2 diabetes. The WHO said the fake medicines could pose a danger to health. The organisation advised people to source the drug only through reputable sources, such as a doctor, rather than obscure sites online or through social media. The active ingredient in Ozempic - semaglutide - helps people with type 2 diabetes control the amount of sugar in their blood. However, the weekly injection also signals to the brain that we're full. So the drug helps people lose weight by reducing the urge to eat. People without diabetes have been getting hold of the drug as a weight-loss medication, which has led to shortages for people with type 2 diabetes and created a market for counterfeit drugs. “[We advise] healthcare professionals, regulatory authorities and the public be aware of these falsified batches of medicines,” said Dr Yukiko Nakatani, WHO assistant director general for essential medicines and health products. "These falsified products could have harmful effects to people’s health," WHO said. Read full story Source: BBC News, 20 June 2024- Posted
-
- Global health
- Medication
-
(and 5 more)
Tagged with:
-
Content Article
This WHO Medical Product Alert refers to three falsified batches of OZEMPIC (semaglutide). This falsified product has been detected in Brazil (October 2023), the United Kingdom of Great Britain and Northern Ireland (October 2023), and the United States of America (December 2023), and was supplied in the regulated supply chain. OZEMPIC (semaglutide) is from a group of medicines called glucagon-like peptide-1 (GLP-1) inhibitors that are indicated for the treatment of hyperglycemia in type 2 diabetes mellitus in adults, adolescents, and children over 12 years of age. The genuine manufacturer of OZEMPIC has confirmed that the three products referenced in this Alert are falsified: the products misrepresent their identify and source as they were not manufactured by Novo Nordisk: batch number LP6F832 is not recognized. the combination of batch number NAR0074 with serial number 430834149057 does not correspond to genuine manufacturing records. batch number MP5E511 is genuine, but the product is falsified.- Posted
-
- Obesity
- Medication
-
(and 4 more)
Tagged with:
-
Content Article
The Canadian Medication Incident Reporting and Prevention System (CMIRPS) is a national voluntary medication incident and ‘near miss’ reporting programme founded for the purpose of sharing the learning experiences from medication errors. Implementation of preventative strategies and system safeguards to decrease the risk for error-induced injury and thereby promote medication safety in healthcare is our collaborative goal. Medication incidents (including near misses) can be reported to ISMP Canada (i) through the website: www.ismpcanada.ca/report/ (ii) by telephone: 416-733-3131 or toll free: 1-866-544-7672.- Posted
-
- Medication
- Canada
-
(and 3 more)
Tagged with: